Lenzetto

Estradiol, the active ingredient in Lenzetto, is an estrogen presented as a transdermal patch for transdermal use. It treats menopausal symptoms and estrogen deficiency in women, helping to restore hormonal balance and alleviate vasomotor and urogenital complaints.

GNH USA supplies Lenzetto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lenzetto, an estrogen replacement therapy, is used to manage conditions related to estrogen deficiency.

Menopausal symptoms: relief of hot flashes, night sweats and vaginal dryness. Estrogen deficiency: restoration of systemic estrogen levels after surgical or natural menopause. Vaginal atrophy: improvement of mucosal health and reduction of dyspareunia.

Lenzetto may cause a range of adverse reactions. The most frequently reported events are generally mild and reversible.

Common Side Effects: - Skin irritation at the patch application site - Headache - Nausea - Breast tenderness

Serious or Rare Side Effects: - Deep vein thrombosis or other thromboembolic events - Stroke or transient ischemic attack - Severe allergic reaction (anaphylaxis)

Before prescribing Lenzetto, clinicians should consider several safety aspects.

Assess cardiovascular risk: evaluate history of thromboembolic disease. Screen for hormone‑sensitive cancers: avoid in active breast or endometrial cancer. Monitor liver function: adjust use in hepatic impairment. Avoid use during pregnancy: contraindicated in pregnant women. Store at room temperature: keep patch in original pouch, protect from moisture and heat.

Estradiol can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Combined hormonal contraceptives: heightened thrombosis risk. - Anticoagulants (e.g., warfarin): possible reduction in anticoagulant effect. - CYP450 inducers (e.g., rifampin): may lower estradiol plasma concentrations.

Moderate Interactions (Monitor Closely): - SSRIs (e.g., fluoxetine): can increase estradiol levels. - Tamoxifen: may antagonize estrogenic activity.